Clinical Trial Update: Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AZD6738 in combination with Olaparib in relapsed small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• AZD6738 (ceralasertib)
• Olaparib (Olaparib)

Snippet

Sponsor: Samsung Medical Center | Conditions: SCLC | Phase 2 | Status: COMPLETED